skip to Main Content

CD40 may be Key to Activating Immune Response in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Researchers at University of Pennsylvania are investigating anti-CD40 antibodies in a number of combinations in pancreatic cancer and other malignancies in which the baseline line immune response against the tumor is insufficient.

Robert H. Vonderheide, MD, DPhil, director of Abramson Cancer Center at Penn, is spearheading a phase 1 study designed to assess whether the addition of the anti-CD40 drug selicrelumab (RO7009789, Roche) to nab-paclitaxel (Abraxane, Celgene) and gemcitabine in the presurgical and postsurgical settings is safe and effective for pancreatic cancer treatment. Read more . . . 

Back To Top